Skeletal metastases: decreasing tumor burden by targeting the bone microenvironment.
Several common cancers often metastasize to the skeleton in advanced disease. Bone metastases are incurable and cause protracted, severe symptoms. Growth of tumor in bone is driven by a vicious cycle: tumor-secreted factors stimulate bone cells, which in turn release growth factors and cytokines. The bone-derived factors fuel the vicious cycle by acting back on the tumor cells. The vicious cycle offers novel targets for the treatment of advanced cancers. Treatments can inhibit bone cells (osteoclasts and osteoblasts) that are stimulated by tumor-secreted factors. Drugs can also inhibit tumor responses to factors enriched in the bone microenvironment, such as transforming growth factor-beta. Animal models show that these approaches, especially combination treatments, can reduce tumor burden. The results suggest a novel paradigm in which tumor growth can be effectively inhibited by drugs that target cells in the bone microenvironment and not the tumor cells themselves.
Chirgwin
John M
JM
The Aurbach Laboratory, Division of Endocrinology, Department of Medicine, University of Virginia, Charlottesville, Virginia 22903, USA. jc3qb@virginia.edu
Guise
Theresa A
TA
D001859:Bone Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000473:pathology* / Q000556:secondary*; D005544:Forecasting; D006801:Humans; D008954:Models, Biological; D009362:Neoplasm Metastasis / Q000188:drug therapy; D010006:Osteoblasts / Q000502:physiology; D010010:Osteoclasts / Q000502:physiology; D010014:Osteolysis / Q000235:genetics / Q000503:physiopathology; D016212:Transforming Growth Factor beta / Q000502:physiology; D047368:Tumor Burden / Q000187:drug effects
D016212:Transforming Growth Factor beta